about
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patientsFertility preservation in women with borderline ovarian tumours.Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923).Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.Fertility preservation in female cancer patients: a single center experienceMental Representations of Illness in Patients with Gestational Trophoblastic Disease: How Do Patients Perceive Their Condition?Clinical presentation of hydatidiform mole in northern Italy: has it changed in the last 20 years?Endometriosis-associated tumor at the inguinal site: report of a case diagnosed during pregnancy and literature review.Hyperreactio luteinalis: timely diagnosis minimizes the risk of oophorectomy and alerts clinicians to the associated risk of placental insufficiency.Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup.Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma.Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus.Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary?Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas.A systematic review on endometriosis during pregnancy: diagnosis, misdiagnosis, complications and outcomes.Female fertility preserving practices at a pediatric unit: a challenge of multiprofessional and multidisciplinary cooperation.Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study.Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.Advances in improving fertility in women through stem cell-based clinical platforms.The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study.Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.Different Patterns of Disease Spread between Advanced-Stage Type I and II Epithelial Ovarian Cancer.Management of bilateral malignant ovarian germ cell tumors: a MITO-9 retrospective study.Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings."Health in the Mirror": An Unconventional Approach to Unmet Psychological Needs in Oncology.Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study.Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9).High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative staging.Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: detection of pelvic nodal metastases.Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.Surgical treatment of elderly patients with endometrial cancer (≥ 65 years).Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma.Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study.Characteristics of clear cell ovarian cancer arising from endometriosis: a two center cohort study.[18F]fluorodeoxyglucose positron emission tomography as a useful indicator of metastatic gestational trophoblastic tumor: preliminary results in three patients.Clear cell and papillary serous endometrial carcinomas: survival in a series of 128 cases.Management of endometrial cancer in Italy: a national survey endorsed by the Italian Society of Gynecologic Oncology.
P50
Q24633820-145B60D0-27B4-4F00-B987-0BF1B002774AQ30248932-3F216937-652F-448F-A17F-12CC075B603CQ33336635-C345B9EC-6881-445F-923A-89596777A3CCQ33348042-C7D24771-AE25-457C-8785-16C58333B8D6Q33365433-6CBC7E8D-81A0-4560-BD7B-A5F57480A65DQ34996163-9F2335C0-DD33-40B2-B92B-817AB578E6A1Q36822168-3A95A12D-F2AF-4983-96E9-735BE76FF01AQ37051675-A9797BB0-2D38-4B38-9D24-233A3CA33CB9Q38194628-E38226A4-6F52-4268-9FE4-327F2B530671Q38196044-730C49BF-B512-4765-A44F-903E5AE509FCQ38262330-E32B994D-35E0-4A3C-B48F-3DF3F342208AQ38262332-09969964-8E0F-4361-9155-D05D92F257ACQ38262341-07EADD0F-7B67-418B-A868-3473D91A8908Q38295160-60F6C5A5-FFF2-4265-8FD8-76C74EF682D8Q38340008-E232F740-320C-4B2F-96B1-CE1E417EA60CQ38602857-F1F18D87-2FBB-4CCC-B42F-6BEAF80F4ABFQ38929681-E6E44932-4F2E-4F61-84E3-BEDA489D7C25Q38946901-741C4B39-B6DB-4D6B-8BDE-EA4B3861EF64Q38995020-A218FEE6-AFE5-472D-8BB6-72C4F20C8D11Q39091640-26DF38F1-1CCC-4305-9E8B-7BA9906233CAQ39205077-DF474A56-255C-4F23-9FCF-B0C6692997F1Q39226352-A2A3874F-C2F3-45DC-8817-31E62743187CQ40197234-184D2270-C615-4C4E-9337-CD820C34FE8DQ40819039-C56C3067-AECC-40FF-964F-63924FADCAAAQ40996187-5B7D8973-A8C4-4A12-97CA-5AA085809809Q41608306-68939F78-6081-4A1A-9936-02574B714DEEQ42164404-A29A865A-9E84-423F-BFE3-3FDFF7F2FD89Q42363876-00F7BA2E-54FF-4AE0-8404-690DD8C85C62Q42951134-0F0C72EB-08EF-4108-9B01-F3A60F40753AQ42990631-486C2332-3410-45C6-A853-302DA85DFA3AQ43157155-372E67BE-8733-4BE8-893C-0491F19F6A4FQ43288732-A66C112E-8961-45A2-9297-E718D4F9324DQ43456129-BC0F35CD-91CD-407F-B96F-465214844088Q43778583-5AE586FB-26F6-41B2-A1DA-D09B967561B0Q44247526-2BEA98AB-3E58-49B6-9DCB-17743BAA9902Q44389865-3AA8E7EF-9DAF-4CA6-BCEA-FE9765DCF0A2Q44584852-944AC353-9F2C-4815-B5DB-DE1232F07023Q44608424-5247FBE0-6136-4F6F-A9D9-5A58270131DEQ45139328-1F58EABD-166A-4A6E-A16F-C5F2F29C10FEQ45375397-95CD5334-DA1B-447C-B3C6-7AE119544B1F
P50
description
researcher
@en
wetenschapper
@nl
name
G Mangili
@en
G Mangili
@nl
type
label
G Mangili
@en
G Mangili
@nl
prefLabel
G Mangili
@en
G Mangili
@nl
P106
P31
P496
0000-0002-8451-429X